Przejdź do zawartości
Merck

Abnormal excitability and episodic low-frequency oscillations in the cerebral cortex of the tottering mouse.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2015-04-10)
Samuel W Cramer, Laurentiu S Popa, Russell E Carter, Gang Chen, Timothy J Ebner
ABSTRAKT

The Ca(2+) channelopathies caused by mutations of the CACNA1A gene that encodes the pore-forming subunit of the human Cav2.1 (P/Q-type) voltage-gated Ca(2+) channel include episodic ataxia type 2 (EA2). Although, in EA2 the emphasis has been on cerebellar dysfunction, patients also exhibit episodic, nonmotoric abnormalities involving the cerebral cortex. This study demonstrates episodic, low-frequency oscillations (LFOs) throughout the cerebral cortex of tottering (tg/tg) mice, a widely used model of EA2. Ranging between 0.035 and 0.11 Hz, the LFOs in tg/tg mice can spontaneously develop very high power, referred to as a high-power state. The LFOs in tg/tg mice are mediated in part by neuronal activity as tetrodotoxin decreases the oscillations and cortical neuron discharge contain the same low frequencies. The high-power state involves compensatory mechanisms because acutely decreasing P/Q-type Ca(2+) channel function in either wild-type (WT) or tg/tg mice does not induce the high-power state. In contrast, blocking l-type Ca(2+) channels, known to be upregulated in tg/tg mice, reduces the high-power state. Intriguingly, basal excitatory glutamatergic neurotransmission constrains the high-power state because blocking ionotropic or metabotropic glutamate receptors results in high-power LFOs in tg/tg but not WT mice. The high-power LFOs are decreased markedly by acetazolamide and 4-aminopyridine, the primary treatments for EA2, suggesting disease relevance. Together, these results demonstrate that the high-power LFOs in the tg/tg cerebral cortex represent a highly abnormal excitability state that may underlie noncerebellar symptoms that characterize CACNA1A mutations.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard
Supelco
Indomethacin, Pharmaceutical Secondary Standard; Certified Reference Material
Caffeine for system suitability, European Pharmacopoeia (EP) Reference Standard
Acetazolamide, European Pharmacopoeia (EP) Reference Standard
USP
Acetazolamide, United States Pharmacopeia (USP) Reference Standard
Supelco
Melting point standard 235-237°C, analytical standard
Sigma-Aldrich
Indole, ≥99%, FG
Sigma-Aldrich
4-Aminopyridine, 98%
Sigma-Aldrich
Indole, ≥99%
Sigma-Aldrich
Pyridine hydrochloride, 98%
Sigma-Aldrich
4-Aminopyridine, ≥99%
Sigma-Aldrich
Chloromethane solution, 1.0 M in diethyl ether
Supelco
Chloromethane solution, 200 μg/mL in methanol, analytical standard
Sigma-Aldrich
Chloromethane solution, 1.0 M in tert-butyl methyl ether, anhydrous
Sigma-Aldrich
DL-2-Amino-5-phosphonopentanoic acid, solid
Sigma-Aldrich
Acetazolamide, ≥99%, powder
Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Indomethacin, 98.5-100.5%, meets EP testing specifications
Indomethacin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Pyridine hydrochloride, purum, ≥98.0% (AT)
USP
Indomethacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Caffeine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Caffeine Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Caffeine, anhydrous, 99%, FCC, FG
Supelco
Caffeine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
USP
Standardowa temperatura topnienia kofeiny, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Caffeine, anhydrous, tested according to Ph. Eur.
Supelco
Mettler-Toledo Calibration substance ME 18872, Caffeine, traceable to primary standards (LGC)
Sigma-Aldrich
DNQX, ≥98% (TLC)
Sigma-Aldrich
Caffeine, Sigma Reference Standard, vial of 250 mg